These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 21250587)

  • 21. [Nephrogenic systemic fibrosis and use of MR contrast media].
    Christiansen RE; Sviland L; Sekse I; Svarstad E
    Tidsskr Nor Laegeforen; 2009 Jan; 129(3):180-2. PubMed ID: 19180161
    [TBL] [Abstract][Full Text] [Related]  

  • 22. How to avoid nephrogenic systemic fibrosis: current guidelines in Europe and the United States.
    Thomsen HS
    Radiol Clin North Am; 2009 Sep; 47(5):871-5, vii. PubMed ID: 19744601
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Involvement of gadolinium chelates in the mechanism of nephrogenic systemic fibrosis: an update.
    Idée JM; Port M; Dencausse A; Lancelot E; Corot C
    Radiol Clin North Am; 2009 Sep; 47(5):855-69, vii. PubMed ID: 19744600
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Nephrogenic fibrosing dermopathy/nephrogenic systemic fibrosis.
    Bertero M; Bainotti S; Comino A; Formica M; Giordano F; Musso L; Palazzini S; Seia Z
    Eur J Dermatol; 2009; 19(1):73-4. PubMed ID: 19171533
    [No Abstract]   [Full Text] [Related]  

  • 25. [Guidelines for administering gadolinium-based contrast agents to patients with renal dysfunction--second edition].
    Hosoya T; Okada H; Horio M; Ohno I; Tamura S; Sugimoto H; Tsushima Y; Hayashi H; Fukuda K; Korogi Y; Yoshifumi N
    Nihon Jinzo Gakkai Shi; 2009; 51(7):839-42. PubMed ID: 19928554
    [No Abstract]   [Full Text] [Related]  

  • 26. Transmetallation and gadolinium: do low iron stores prevent the development of nephrogenic systemic fibrosis in high-risk end-stage renal disease patients?
    Panesar M; Boateng F; Patel SS; Masood SF; Mahajan P; Patel N; Murray B
    Hemodial Int; 2010 Jul; 14(3):289-94. PubMed ID: 20662951
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Gadolinium-based contrast agents and NSF: evidence from animal experience.
    Sieber MA; Steger-Hartmann T; Lengsfeld P; Pietsch H
    J Magn Reson Imaging; 2009 Dec; 30(6):1268-76. PubMed ID: 19938039
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Rehabilitation in nephrogenic systemic fibrosis.
    Ramaizel L; Sliwa JA
    PM R; 2009 Jul; 1(7):684-6. PubMed ID: 19627963
    [No Abstract]   [Full Text] [Related]  

  • 29. Nephrogenic systemic fibrosis: a review of the new conundrum.
    Goenka AH; Das CJ; Sharma R
    Natl Med J India; 2009; 22(6):302-6. PubMed ID: 20384019
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Gadolinium and nephrogenic systemic fibrosis: association or causation.
    Kurtkoti J; Snow T; Hiremagalur B
    Nephrology (Carlton); 2008 Jun; 13(3):235-41. PubMed ID: 18221255
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Current status of gadolinium toxicity in patients with kidney disease.
    Perazella MA
    Clin J Am Soc Nephrol; 2009 Feb; 4(2):461-9. PubMed ID: 19201920
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Prevalence of NSF following intravenous gadolinium-contrast media administration in dialysis patients with endstage renal disease.
    Heinz-Peer G; Neruda A; Watschinger B; Vychytil A; Geusau A; Haumer M; Weber M
    Eur J Radiol; 2010 Oct; 76(1):129-34. PubMed ID: 19619969
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Nephrogenic systemic fibrosis associated with gadolinium based contrast agents: a summary of the medical literature reporting.
    Broome DR
    Eur J Radiol; 2008 May; 66(2):230-4. PubMed ID: 18372138
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Nephrogenic system fibrosis: a radiologist's practical perspective.
    Martin DR
    Eur J Radiol; 2008 May; 66(2):220-4. PubMed ID: 18321672
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Nephrogenic systemic fibrosis and its impact on abdominal imaging.
    Prince MR; Zhang HL; Prowda JC; Grossman ME; Silvers DN
    Radiographics; 2009 Oct; 29(6):1565-74. PubMed ID: 19959508
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Nephrogenic systemic fibrosis: pathogenesis, diagnosis, and therapy.
    Kribben A; Witzke O; Hillen U; Barkhausen J; Daul AE; Erbel R
    J Am Coll Cardiol; 2009 May; 53(18):1621-8. PubMed ID: 19406336
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Nephrogenic systemic fibrosis and management of high-risk patients.
    Altun E; Semelka RC; Cakit C
    Acad Radiol; 2009 Jul; 16(7):897-905. PubMed ID: 19375360
    [TBL] [Abstract][Full Text] [Related]  

  • 38. MRI safety: nephrogenic systemic fibrosis and other risks.
    Gauden AJ; Phal PM; Drummond KJ
    J Clin Neurosci; 2010 Sep; 17(9):1097-104. PubMed ID: 20542435
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Nephrogenic systemic fibrosis in advanced chronic kidney disease: a single hospital's experience in Taiwan.
    Chen W; Huang SL; Huang CS; Tsai MC; Lai HM; Lui CC; Eng HL; Chang HW; Lee CH; Chuang FR
    Eur J Dermatol; 2009; 19(1):44-9. PubMed ID: 19059824
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Nephrogenic systemic fibrosis: report of an additional case with granulomatous inflammation.
    Wilford C; Fine JD; Boyd AS; Sanyal S; Abraham JL; Kantrow SM
    Am J Dermatopathol; 2010 Feb; 32(1):71-5. PubMed ID: 19940755
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.